Skip to content

Study · Randomized controlled trial · n = 19 · 2006

6 results

Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.

Laferrère B, Hart AB, Bowers CY

Obesity (Silver Spring, Md.)1 Jun 2006Cited by 13 (Europe PMC)

PMID16861611 (opens in a new tab)PMCIDPMC2824649 (opens in a new tab)DOI10.1038/oby.2006.121 (opens in a new tab)PepBankPUB-16861611
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In lean and obese subjects, low-dose GHRP‑2 infusion increased ad libitum food intake by 10.2% compared with placebo.

    In plain wordsIn lean and obese people, a low GHRP‑2 infusion made them eat about 10% more than placebo at a buffet lunch.

    Peptide
    GHRP-2
    Outcome
    IncreaseAd libitum food intake at low dose
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1 microg/kg per hour · subcutaneous infusion · 270 minutesAs given in this study (human).

    Measurements

    Increase in ad libitum food intake
    10.2%
    low dose

    Source sentences

    Summary
    GHRP-2 infusion significantly increased ad libitum FI in a dose-dependent manner by 10.2 +/- 3.9% at low dose (p = 0.011) and by 33.5 +/- 5.8% at HD (p = 0.000) compared with placebo.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In lean and obese subjects, high-dose GHRP‑2 infusion increased ad libitum food intake by 33.5% compared with placebo.

    In plain wordsIn lean and obese people, a high GHRP‑2 infusion made them eat 33.5% more than placebo at a buffet lunch.

    Peptide
    GHRP-2
    Outcome
    IncreaseAd libitum food intake at high dose
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 mug/kg per hour · subcutaneous infusion · 270 minutesAs given in this study (human).

    Measurements

    Increase in ad libitum food intake
    33.5%
    high dose

    Source sentences

    Summary
    GHRP-2 infusion significantly increased ad libitum FI in a dose-dependent manner by 10.2 +/- 3.9% at low dose (p = 0.011) and by 33.5 +/- 5.8% at HD (p = 0.000) compared with placebo.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.
  3. 03HumanRandomized controlled trialEfficacy outcome

    Obesity status did not change the effect of GHRP‑2 on food intake.

    In plain wordsGHRP‑2 raised food intake to a similar degree in obese and lean people.

    Peptide
    GHRP-2
    Outcome
    No significant changeEffect of obesity status on the food intake response
    Study

    n = 19

    Comparator
    Lean subjects
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous infusion · 270 minutesAs given in this study (human).

    Source sentences

    Summary
    Obesity status did not influence the effect of GHRP-2 on FI.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In all subjects, high-dose GHRP‑2 gave greater appetite ratings before the meal than placebo.

    In plain wordsWith the high GHRP‑2 dose, all subjects felt hungrier before the meal than with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseAppetite ratings before the meal at high dose
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 mug/kg per hour · subcutaneous infusion · 270 minutesAs given in this study (human).

    Source sentences

    Summary
    All subjects had greater ratings of appetite before but similar levels of fullness after the meal with the HD GHRP-2.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In all subjects, fullness ratings after the meal were similar with high-dose GHRP‑2 and placebo.

    In plain wordsAfter the meal, feelings of fullness were similar with the high GHRP‑2 dose and with placebo.

    Peptide
    GHRP-2
    Outcome
    No significant changeFullness ratings after the meal at high dose
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 mug/kg per hour · subcutaneous infusion · 270 minutesAs given in this study (human).

    Source sentences

    Summary
    All subjects had greater ratings of appetite before but similar levels of fullness after the meal with the HD GHRP-2.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.
  6. 06HumanRandomized controlled trialActivity measurement

    In all subjects, GHRP‑2 infusion raised serum GH levels in a dose-dependent manner.

    In plain wordsIn all subjects, GHRP‑2 raised growth hormone levels, and a higher dose raised them more.

    Peptide
    GHRP-2
    Outcome
    IncreaseSerum GH levels
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous infusion · 270 minutesAs given in this study (human).

    Source sentences

    Summary
    Serum GH levels increased dose dependently in all subjects.
    1 context sentence
    Summary · context
    Nineteen subjects (10 lean and nine obese), all healthy and weight stable, received a double-blind randomized subcutaneous infusion of GHRP-2 at high dose (HD; 1 mug/kg per hour), low dose (0.1 microg/kg per hour), or placebo for 270 minutes over three study visits.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.